Skip to main content
SpringerLink
Log in

Comparative In Vitro Activities of Fluconazole, Voriconazole, and MXP-4509 Against Romanian Blood Yeast Isolates

  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

The aim of the study was to evaluate the antifungal activity of a new triazole formulation against 182 clinical isolates of yeasts recovered from blood cultures in three tertiary hospitals in Romania and to compare its activity with those of fluconazole and voriconazole. In vitro susceptibility was assessed by following the guidelines of AFST-EUCAST E. Def. 7.1. The distribution of minimum inhibitory concentrations (MICs) of MXP-4509 was very similar to that of voriconazole (MIC50: 0.0312 mg/l vs. 0.0156 mg/l; MIC90: 0.25 mg/l vs. 0.25 mg/l), but significantly different from that of fluconazole (MIC50: 0.0312 mg/l vs. 0.5 mg/l; MIC90: 0.25 mg/l vs. 32 mg/l). The new triazole MXP-4509 proved to have a good in vitro antifungal activity raising the interest for further pharmacological and microbiological investigations in order to assess its potential advantages for therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010; 48(4):1366–77.

    Google Scholar 

  2. Pfaller MA, Espinel-Ingroff A, Boyken L et al. Comparison of the broth microdilution (BMD) method of the European committee on antimicrobial susceptibility testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol. 2011; 49(3):845–50.

    Google Scholar 

  3. Lyon GM, Karatela S, Sunay S, et al. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010;48(4):1270–5.

    Article  PubMed  CAS  Google Scholar 

  4. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47(10):3149–54.

    Article  PubMed  CAS  Google Scholar 

  5. Quindos G, Sanchez-Varga LO, Villar-Vidal M, et al. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Int J Antimicrob Agents. 2008;31(3):266–71.

    Article  PubMed  CAS  Google Scholar 

  6. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171–9.

    Article  PubMed  CAS  Google Scholar 

  7. Szejtli J. Past, present, and future of cyclodextrin research. Pure Appl Chem. 2004;76(10):1825–45.

    Article  CAS  Google Scholar 

  8. Spulber M, Miron L, Mareş M, et al. Water soluble 5-FC complexes, preliminary pharmacological studies. J Incl Phenom Macrocycl Chem. 2009;65:431–5.

    Article  CAS  Google Scholar 

  9. Miron L, Mareş M, Năstasă V, et al. Water soluble sulconazole-beta-cyclodextrin complex: physico-chemical characterization and preliminary pharmacological studies. J Incl Phenom Macrocycl Chem. 2009;63:159–62.

    Article  CAS  Google Scholar 

  10. Mareş M, Ştefanache A, Popovici I, et al. Evaluation of the antifungal effect of a new propiconazole derivative against 64 yeast strains isolated from vaginal mycoses. Fungi Mycotox. 2007;2:83–7.

    Google Scholar 

  11. Goetz KA, Dix JD. Mode of action for reproductive and hepatic toxicity inferred from a genomic study of triazole antifungals. Toxicol Sci. 2009;110(2):449–62.

    Article  PubMed  CAS  Google Scholar 

  12. Chen P-J, Moore T, Nesnow S. Cytotoxic effects of propiconazole and its metabolites in mouse and human hepatoma cells and primary mouse hepatocytes. Toxicol In Vitro. 2008;22:1476–83.

    Article  PubMed  CAS  Google Scholar 

  13. World Health Organisation. The WHO recommended classification of pesticides by hazard and guidelines to classification. Geneva: WHO Press; 2010.

    Google Scholar 

  14. Pfizer Inc. Vfend (Voriconazole) Powder for oral suspension. Material safety data sheet; version 1.2; 2007.

  15. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F, et al. EUCAST definitive document E Def 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398–405.

    Article  CAS  Google Scholar 

  16. Dannaoui E, Lortholary O, Raoux D, et al. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European committee on antimicrobial susceptibility testing, against yeast isolates obtained in France in 2005–2006. Antimicrob Agents Chemother. 2008;52(2):778–81.

    Article  PubMed  CAS  Google Scholar 

  17. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, et al. EUCAST technical note on fluconazole. Clin Microbiol Infect. 2008;14(2):193–5.

    Google Scholar 

  18. Espinel-Ingroff A, Pfaller M, Cantón E, et al. Emerging resistance to azoles and echinocandins: clinical relevance and laboratory detection. Curr Fungal Infect Rep. 2010;4(3):186–95.

    Article  Google Scholar 

  19. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, et al. EUCAST technical note on voriconazole. Clin Microbiol Infect. 2008;14(10):985–7.

    Article  Google Scholar 

  20. Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs. 2004;5:186–97.

    PubMed  CAS  Google Scholar 

  21. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK global antifungal surveillance program. Diag Microbiol Infect Dis. 2010;67(2):162–71.

    Google Scholar 

  22. Sellami A, Sellami H, Neji S, et al. Antifungal susceptibility of bloodstream Candida isolates in Sfax Hospital: Tunisia. Mycopathol. 2010;171(6):417–22.

    Article  Google Scholar 

Download references

Acknowledgments

The authors are indebted to Maria Mirela Flonta, Ariana Almaş, Maria Cîrlan, Maria Dan, Doina Veronica Bilcă, and Annamaria Foldes, who kindly supplied some of the clinical isolates used in this study, as well as Valeria Harabagiu, Mariana Pinteală, and Narcisa Marangoci for the synthesis of MXP-4509 nanoconjugates. This work was supported by the Ministry of Education and Research from Romania—CNCSIS-UEFISCSU, project number PN II-RU 159/2010.

Conflict of Interests

None.

Author information

Authors and Affiliations

  1. Laboratory of Antimicrobial Chemotherapy, Ion Ionescu de la Brad University, 8 Aleea Sadoveanu, P4, 1st floor, 700489, Iaşi, Romania

    Mihai Mareş, Valentin Năstasă, Florina Moraru Ramona & Bogdan Doroftei

  2. 2nd Obstetrics-Gynecology Clinic, “Gr. T. Popa” University of Medicine and Pharmacy, 16 Universităţii Street, 700115, Iaşi, Romania

    Bogdan Doroftei

  3. Faculty of Pharmacy, “Gr. T. Popa” University of Medicine and Pharmacy, 16 Universităţii Street, 700115, Iaşi, Romania

    Alina Ştefanache

Authors
  1. Mihai Mareş
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentin Năstasă
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Florina Moraru Ramona
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bogdan Doroftei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alina Ştefanache
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mihai Mareş.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mareş, M., Năstasă, V., Moraru Ramona, F. et al. Comparative In Vitro Activities of Fluconazole, Voriconazole, and MXP-4509 Against Romanian Blood Yeast Isolates. Mycopathologia 172, 487–492 (2011). https://doi.org/10.1007/s11046-011-9455-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-011-9455-1

Keywords

Search

Navigation